Pharmacovigilance In India: A Review of ADR Monitoring, Education and Systemic Advancement

India established a system for tracking adverse drug reactions in 1986 and joined the WHO Programme for International Drug Monitoring in 1998. The National Programme of Pharmacovigilance was renamed the Pharmacovigilance Programme of India (PvPI) in 2010, aiming to protect the Indian population’s health.Pharmacovigilance is the science of preventing harmful effects of pharmaceutical medicines, involving pharmacists. It’s crucial in healthcare, identifying potential drugs, analyzing drug interactions, and monitoring adverse effects. This study examines drug store students’ perspectives on pharmacovigilance and ADR announcements during undergraduate education. Pharmacovigilance (PV) is crucial in healthcare for monitoring drug interactions and adverse drug reactions (ADRs) throughout a drug’s life cycle. It involves pharmacogenomics and pharmacogenomics, focusing on detecting, understanding, and preventing these risks, ensuring medication safety. The PV system team collects data to enhance the scientific material in initial reports, promoting strict monitoring of adverse effects and efficient medication approval regulations. PV systems’ proximity to the population and public health professionals allows for easy communication with reporters, highlighting the joint responsibility of pharmaceutical businesses, drug regulators, and physicians.